Malfunction in WIPO Sequence version 2.1.1

The EPO is aware of a malfunction in the WIPO Sequence 2.1.1. tool for creating sequence listings compliant with WIPO Standard ST.26. The technical malfunction can lead to the deletion of the entire feature table for a particular SEQ ID. The malfunction appears to occur upon generation of the sequence listing. Therefore, applicants are strongly recommended to also validate each sequence listing using the ‘Validate Sequence Listing' function of WIPO Sequence after generating the sequence listing and before uploading them in the filing tool. If no error message is displayed during this second validation this should allow applicants to exclude that the malfunction has occurred.

  1. If an error message is displayed during the second validation and a sequence listing has been effected by the technical malfunction, with the consequence that the feature table for a SEQ ID has been deleted, the issue may be resolved as follows:
  2. Go to WIPO Sequence software and press on ‘Import sequence listing'.
  3. Give a different name to the project so that you will be able to find it back in the list of projects.
  4. Check the boxes to import all general information part and all sequences.
  5. Once the sequence listing has been imported, navigate to the sequence that has the error.
  6. You will notice that the qualifiers mol_type and organism of the ‘source' feature are blank, i.e., they contain no data.
  7. Add the correct data to the qualifiers mol_type and organism as you did in the initial project.
  8. Add any other feature (if applicable).
  9. Validate the project.
  10. Generate the sequence listing.
  11. Validate the sequence listing by using ‘Validate Sequence Listing' function of WIPO Sequence.
  12. This time there should be NO error about a missing feature table for the given sequence.

Applicants are also strongly recommended not to delete the project files for sequence listings.

We apologise for any inconvenience. Please always refer to the title of this notice when addressing the EPO in relation to this issue.

Quick Navigation